Long-term follow-up for hepatitis B treatment
Part of Digestive system, Infections clinical trials.
This study follows patients who completed a previous trial of peginterferon alfa-2b and tenofovir for chronic hepatitis B. It checks long-term health and offers further treatment options based on your response to the earlier therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have completed the previous TB1901IFN study, taking most of the medications or stopping early as per the study rules.
- You volunteer to join and understand the study details.
- You do not have liver cancer.
- Depending on your liver virus levels from the prior study, you may be placed in a group that needs certain infection markers or be willing to take more medication.
- If you join the group that continues medication, you must not be pregnant, breastfeeding, or planning pregnancy during treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at genetic factors that may help people with chronic hepatitis B achieve a clinical cure when treated with long-acting interferon. It aims to find out why some patients respond better than others.
This trial is for people with chronic hepatitis B who have already cleared the virus with interferon treatment. It tests ongoing strategies to help maintain their health and prevent the virus from coming back.
This study tests a new combination of antiviral medicine and an immune-boosting therapy for adults with chronic hepatitis B. It is designed for people who are in the active phase of the infection and have not been treated before.
This study looks at long-term outcomes in people with chronic hepatitis B who take antiviral medicines or receive interferon. It may help doctors understand which treatments work best over time and who is most likely to benefit.
This trial tests a retreatment with pegylated interferon for people with chronic hepatitis B who have previously received interferon therapy and have seen their hepatitis B surface antigen (HBsAg) levels drop by at least half. The goal is to see if this retreatment can completely clear the virus from the blood.
This study looks at whether extra treatment with peginterferon (a drug that boosts the immune system) can help lower the amount of hidden hepatitis B virus in the liver after you've already reached clinical cure. You'll have two liver biopsies to measure this, and the findings may help prevent the virus from coming back.
Hear when a new Chronic Hepatitis B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.